Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, ...

Entered into broad strategic collaboration with Eli Lilly and Company ('Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...

The Food and Drug Administration has extended the review period for setmelanotide in the treatment of acquired hypothalamic obesity.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Reports Q3 revenue $410,000 vs. $10.9M last year. “Following the close of the third quarter, we are very pleased to have signed a strategic ...

Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on ...

Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. 8 Natural Alternatives to Ozempic for Weight Loss Ozempic®, ...